Abstract 5368
Background
Neoadjuvant chemotherapy (NAC) has become as the preferred initial therapy for locally advanced breast cancer (LABC) patients. A pathologic complete response (pCR) following NAC correlates strongly with both prolonged disease-free survival and overall survival especially for patients with HER2+ or triple negative breast cancer (TNBC). A lot of modalities and molecular markers for assessing chemotherapy response have been evaluated; however, they have demonstrated only limited predictive value.
Methods
Plasma samples have been collected from 167 patients diagnosed with LABC and received NAC from month, year to month, year prospectively. Samples were collected three times from each patient, prior to NAC (pre-treatment), prior to second cycle of NAC (on-treatment), and after breast surgery (post-treatment). Samples were assayed by multiplex immunoassays for 45 biomarkers. Plasma biomarker levels using Cytokine/Chemokine/Growth Factor 45-Plex Human ProcartaPlexTM Panel were compared with pathologic treatment responses. pCR was defined as the absence of residual tumor both in breast and axillary lymph nodes. This study was approved by the Institutional Review Board of Samsung Medical Center (SMC 2014-11-015-017).
Results
A median age at diagnosis of the 167 patients was 42 (range, 23-68 years). Most of the patients were treated with anthracycline and taxane-based regimen including adriamycin with cyclophosphamide plus docetaxel (AC-T), or AC-T plus trastuzumab. The patients were divided into the following four groups: HR+/HER2- (n = 46, 28%), HR+/HER2 + (n = 26, 16%), HR-/HER2 + (n = 32, 19%), and TNBC (n = 63, 38%). Thirty four patients (20%) achieving a pCR were compared with 133 patients (80%) demonstrating no pCR. Several groups of biomarker expression, BDNF, bNGF, HGF, IFN-gamma, IL-18, IP-10, MCP-1, RANTES, and SCF, were significantly different among pre-treatment, on-treatment and post-treatment. Multivariate analysis on pCR showed that analysis using the multiplex panel has predictive power.
Conclusions
Plasma biomarkers including immune-cytokine may have a role to predict treatment response in the neoadjuvant setting.
Clinical trial identification
Legal entity responsible for the study
Samsung Medical Center.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract